Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: A meta-analysis

Clinical Endocrinology

Volumn 74, Issue 3, 2011, Pages 332-339

  Li, X J ^a,b,c   Yu, Y X ^b,c   Liu, C Q ^b,c   Zhang, W ^c   Zhang, H J ^b,c   Yan, B ^b,c   Wang, L Y ^b,c   Yang, S Y ^b,c   Zhang, S H ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

^c Xiamen Diabetes Institute   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; CHOLESTEROL; CLOMIFENE CITRATE; FOLLITROPIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; METFORMIN; PIOGLITAZONE; PRASTERONE SULFATE; ROSIGLITAZONE; TESTOSTERONE; TRIACYLGLYCEROL;

ABDOMINAL CRAMP; ANDROGEN BLOOD LEVEL; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOLLITROPIN BLOOD LEVEL; HEADACHE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUAL CYCLE; META ANALYSIS; NAUSEA; OVARY POLYCYSTIC DISEASE; OVULATION; PREGNANCY RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

EID: 79851497520     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2010.03917.x     Document Type: Article

References (50)

1. Azziz, R., Woods, K.S., Reyna, R., et al. (2004) The prevalence and features of the polycystic ovary syndrome in an unselected population. Journal of Clinical Endocrinology and Metabolism 89, 2745-2749. (Pubitemid 38766360)
2. Escobar-Morreale, H.F., Roldán, B., Barrio, R., et al. (2000) High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 85, 4182-4187. (Pubitemid 32055370)
3. Asunciõn, M., Calvo, R.M., San. Millán, J.L., et al. (2000) A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. Journal of Clinical Endocrinology and Metabolism 85, 2434-2438.
4. Legro, R.S., Kunselman, A.R., Dodson, W.C., et al. (1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. Journal of Clinical Endocrinology and Metabolism 84, 165-169. (Pubitemid 29036695)
5. Diamanti-Kandarakis, E., Kouli, C.R., Bergiste, A.T., et al. (1999) A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. Journal of Clinical Endocrinology and Metabolism 84, 4006-4011. (Pubitemid 30644187)
6. Kouvunen, R., Laatikaanen, T., Tomas, C., et al. (1999) The prevalence of polycystic ovaries in healthy women. Acta Obstetricia et Gynecologica Scandinavica 78, 137-144.
7. Nisenblat, V., &, Norman, R.J., (2009) Androgens and polycystic ovary syndrome. Current Opinion in Endocrinology, Diabetes, and Obesity, 16, 224-231.
8. Nardo, L.G., Patchava, S., &, Laing, I., (2008) Polycystic ovary syndrome: pathophysiology, molecular aspects and clinical implications. Panminerva Medica, 50, 267-278.
9. Khan, K.A., Stas, S., &, Kurukulasuriya, L.R., (2006) Polycystic ovarian syndrome. Journal of the Cardiometabolic Syndrome, 1, 125-130.
10. Ehrmann, D.A., Sturis, J., Byrne, M.M., et al. (1995) Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. Journal of Clinical Investigation, 96, 520-527.
11. Nestler, J.E., &, Jakubowicz, D.J., (1996) Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. New England Journal of Medicine, 335, 617-623. (Pubitemid 26277951)
12. Diamanti-Kandarakis, E., &, Papavassiliou, A.G., (2006) Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends in Molecular Medicine, 12, 324-332. (Pubitemid 44094292)
13. Pasquali, R., &, Gambineri, A., (2006) Insulin-sensitizing agents in polycystic ovary syndrome. European Journal of Endocrinology, 154, 763-775. (Pubitemid 43997712)
14. Katsiki, N., Georgiadou, E., &, Hatzitolios, A.I., (2009) The role of insulin-sensitizing agents in the treatment of polycystic ovary syndrome. Drugs, 69, 1417-1431.
15. Nestler, J.E., Jakubowicz, D.J., de Vargas, A.F., et al. (1998) Insulin stimulates testosterone biosynthesis by human theca cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. Journal of Clinical Endocrinology and Metabolism, 83, 2001-2005. (Pubitemid 28496328)
16. Vignesh, J.P., &, Mohan, V., (2007) Polycystic ovary syndrome: a component of metabolic syndrome? Journal of Postgraduate Medicine, 53, 128-134. (Pubitemid 46808818)
17. Willis, D., &, Franks, S., (1995) Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-I insulin-like growth factor receptor. Journal of Clinical Endocrinology and Metabolism 80, 3788-3790.
18. Amin, M., Abdel-Kareem, O., Takekida, S., et al. (2003) Minireview: up-date management of non responder to clomiphene citrate in polycystic ovary syndrome. Kobe Journal of Medical Sciences, 49, 59-73. (Pubitemid 38477600)
19. Cheang, K.I., Sharma, S.T., &, Nestler, J.E., (2006) Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome? Gynecological Endocrinology, 22, 595-604. (Pubitemid 44915725)
20. Velazquez, E.M., Mendoza, S., Hamer, T., et al. (1994) Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism, 43, 647-654. (Pubitemid 24145474)
21. Wang, H.S., (2006) The role of metformin in the treatment of polycystic ovary syndrome (PCOS). Chang Gung Medical Journal, 29, 445-447.
22. Lord, J.M., Flight, I.H., &, Norman, R.J., (2003) Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ, 327, 951-953.
23. Aruna, J., Mittal, S., Kumar, S., et al. (2004) Metformin therapy in women with polycystic ovary syndrome. International Journal of Gynaecology and Obstetrics, 87, 237-241. (Pubitemid 39535085)
24. Genazzani, A.D., Battaglia, C., Malavasi, B., et al. (2004) Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertility and Sterility, 81, 114-119. (Pubitemid 38058335)
25. Palomba, S., Orio Jr, F., Nardo, L.G., et al. (2004) Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism, 89, 4801-4809. (Pubitemid 39391410)
26. Vanky, E., Salvesen, K.A., Heimstad, R., et al. (2004) Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Human Reproduction, 19, 1734-1740. (Pubitemid 39144614)
27. Dunaif, A., (2008) Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome-a reappraisal. Nature Clinical Practice. Endocrinology & Metabolism, 5, 272-281.
28. Tang, T., Lord, J.M., Normal, R.J., et al. (2010) Insulin-sensitizing drugs (meformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligomenorrhoea and subfertility. Cochrane Database of Systematic Reviews CD003053.
29. Aroda, V.R., Ciaraldi, T.P., Burke, P., et al. (2009) Metabolic and hormonal changes Induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. Journal of Clinical Endocrinology and Metabolism, 94, 469-476.
30. Yilmaz, M., Karakoc, A., Törüner, F.B., et al. (2005) The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecological Endocrinology, 21, 154-160. (Pubitemid 41597556)
31. Yilmaz, M., Bukan, N., Ayvaz, G., et al. (2005) The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Human Reproduction, 20, 3333-3340. (Pubitemid 41742509)
32. Jensterle, M., Sebestjen, M., Janez, A., et al. (2008) Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome. European Journal of Endocrinology, 159, 399-406.
33. Jüni, P., Altman, D.G., &, Egger, M., (2001) Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ, 323, 42-46. (Pubitemid 32682008)
34. Rouzi, A.A., &, Ardawi, M.S., (2006) A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. Fertility and Sterility, 85, 428-435. (Pubitemid 43170918)
35. Ortega-González, C., Luna, S., Hernández, L., et al. (2005) Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 90, 1360-1365. (Pubitemid 40463988)
36. Cho, L.W., Kilpatrick, E.S., Keevil, B.G., et al. (2009) Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. Clinical Endocrinology, 70, 233-237.
37. Baillargeon, J.P., Jakubowicz, D.J., Iuorno, M.J., et al. (2004) Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility, 82, 893-902. (Pubitemid 39346435)
38. Mitkov, M., Pehlivanov, B., &, Terzieva, D., (2006) Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome. European Journal of Obstetrics, Gynaecology, and Reproductive Biology, 126, 93-98. (Pubitemid 44294601)
39. Kilicdag, E.B., Bagis, T., Zeyneloglu, H.B., et al. (2005) Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Human Reproduction, 20, 894-899. (Pubitemid 40667831)
40. Yilmaz, M., Biri, A., Karakoc, A., et al. (2005) The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. Journal of Endocrinological Investigation, 28, 1003-1008. (Pubitemid 43265766)
41. Kushner, R.F., &, Sujak, M., (2009) Prevention of weight gain in adult patients treated with pioglitazone. Obesity (Silver Spring) 17, 1017-1022.
42. Diamanti-Kandarakis, E., Christakou, C.D., Kandaraki, E., et al. (2010) Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. European Journal of Endocrinology, 162, 193-212.
43. Alivanis, P., Giannikouris, I., Paliuras, C., et al. (2006) Metformin-associated lactic acidosis treated with continuous renal replacement therapy. Clinical Therapeutics, 28, 396-400. (Pubitemid 43783435)
44. Bell, D.S., (2010) Merformin-induced vitamin B12 deficiency presenting as a peripheral neuropathy. Southern Medical Journal, 103, 265-267.
45. De Jaeger, J., Kooy, A., Lehert, P., et al. (2010) Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: a randomized placebo-controlled trial. BMJ, 340, c2181.
46. Bodmer, M., Meier, C., Kraenzlin, M.E., et al. (2009) Risk of fractures with glitazones: a critical review of the evidence to date. Drug Safety, 32, 539-547.
47. Nissen, S.E., &, Wolski, K., (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New England Journal of Medicine, 356, 2457-2471. (Pubitemid 46919772)
48. Schwartz, S., Fonseca, V., Berner, B., et al. (2006) Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care, 29, 759-764. (Pubitemid 44115290)
49. Hellmuth, E., Damm, P., &, Molsted-Pedersen, L., (2000) Oral hypoglycemic agents in 118 diabetic pregnancies. Diabetic Medicine, 17, 507-511. (Pubitemid 30660151)
50. Rowan, J.A., Hague, W.M., Gao, W., et al. (2008) Metformin versus insulin for the treatment gestational diabetes. The New England Journal of Medicine, 358, 2003-2015. (Pubitemid 351656455)